-
Methods in Molecular Biology (Clifton,... 2021Vaccination was developed by Edward Jenner in 1796. Since then, vaccination and vaccine development research has been a hotspot of research in the scientific community....
Vaccination was developed by Edward Jenner in 1796. Since then, vaccination and vaccine development research has been a hotspot of research in the scientific community. Various ways of vaccine development are successfully employed in mass production of vaccines. One of the most successful ways to generate vaccines is the method of virulence attenuation in pathogens. The attenuated strains of viruses, bacteria, and parasites are used as vaccines which elicit robust immune response and confers protection against virulent pathogens. This chapter brings together the most common and efficient ways of generating live attenuated vaccine strains in viruses, bacteria, and parasites.
Topics: Animals; Bacterial Vaccines; Cell Line; Codon Usage; Female; Gamma Rays; Gene Silencing; Humans; Immunization; Immunogenicity, Vaccine; Influenza A virus; Mice; MicroRNAs; Models, Animal; Mutagenesis; Orthomyxoviridae Infections; Protozoan Vaccines; Radiation, Ionizing; Vaccines, Attenuated; Vaccinology; Virulence
PubMed: 32959252
DOI: 10.1007/978-1-0716-0795-4_17 -
PLoS Pathogens Sep 2018
Review
Topics: Animals; Diarrhea; Giardia lamblia; Giardiasis; Humans; Protozoan Vaccines; Vacuoles
PubMed: 30261050
DOI: 10.1371/journal.ppat.1007250 -
Canadian Journal of Gastroenterology &... 2018is the responsible parasite of amoebiasis and remains one of the top three parasitic causes of mortality worldwide. With increased travel and emigration to developed... (Review)
Review
is the responsible parasite of amoebiasis and remains one of the top three parasitic causes of mortality worldwide. With increased travel and emigration to developed countries, infection is becoming more common in nonendemic areas. Although the majority of individuals infected with remain asymptomatic, some present with amoebic colitis and disseminated disease. As more is learned about its pathogenesis and the host's immune response, the potential for developing a vaccine holds promise. This narrative review outlines the current knowledge regarding and and insight in the development of a vaccine.
Topics: Antiprotozoal Agents; Dysentery, Amebic; Entamoeba histolytica; Entamoebiasis; Humans; Protozoan Vaccines; Travel
PubMed: 30631758
DOI: 10.1155/2018/4601420 -
The Lancet. Infectious Diseases Jan 2015Cryptosporidium spp are well recognised as causes of diarrhoeal disease during waterborne epidemics and in immunocompromised hosts. Studies have also drawn attention to... (Review)
Review
Cryptosporidium spp are well recognised as causes of diarrhoeal disease during waterborne epidemics and in immunocompromised hosts. Studies have also drawn attention to an underestimated global burden and suggest major gaps in optimum diagnosis, treatment, and immunisation. Cryptosporidiosis is increasingly identified as an important cause of morbidity and mortality worldwide. Studies in low-resource settings and high-income countries have confirmed the importance of cryptosporidium as a cause of diarrhoea and childhood malnutrition. Diagnostic tests for cryptosporidium infection are suboptimum, necessitating specialised tests that are often insensitive. Antigen-detection and PCR improve sensitivity, and multiplexed antigen detection and molecular assays are underused. Therapy has some effect in healthy hosts and no proven efficacy in patients with AIDS. Use of cryptosporidium genomes has helped to identify promising therapeutic targets, and drugs are in development, but methods to assess the efficacy in vitro and in animals are not well standardised. Partial immunity after exposure suggests the potential for successful vaccines, and several are in development; however, surrogates of protection are not well defined. Improved methods for propagation and genetic manipulation of the organism would be significant advances.
Topics: Antiprotozoal Agents; Cryptosporidiosis; Diagnostic Tests, Routine; Diarrhea; Global Health; Humans; Protozoan Vaccines
PubMed: 25278220
DOI: 10.1016/S1473-3099(14)70772-8 -
Trends in Parasitology Dec 2023Chicken coccidiosis, caused by infection with single or multiple Eimeria species, results in significant economic losses to the global poultry industry. Over the past... (Review)
Review
Chicken coccidiosis, caused by infection with single or multiple Eimeria species, results in significant economic losses to the global poultry industry. Over the past decades, considerable efforts have been made to generate attenuated Eimeria strains, and the use of live attenuated anticoccidial vaccines for disease prevention has achieved tremendous success. In this review, we evaluate the advantages and limitations of the methods of attenuation as well as attenuated Eimeria strains in a historical perspective. Also, we summarize the recent exciting research advances in transient/stable transfection systems and clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing developed for Eimeria parasites, and discuss trends and challenges of developing live attenuated anticoccidial vaccines based on transgenesis and genome editing.
Topics: Animals; Chickens; Vaccines, Attenuated; Poultry Diseases; Protozoan Vaccines; Coccidiosis; Eimeria
PubMed: 37770352
DOI: 10.1016/j.pt.2023.09.002 -
Frontiers in Cellular and Infection... 2017Vaccination is an efficient means of combating infectious disease burden globally. However, routine vaccines for the world's major human parasitic diseases do not yet... (Review)
Review
Vaccination is an efficient means of combating infectious disease burden globally. However, routine vaccines for the world's major human parasitic diseases do not yet exist. Vaccines based on carbohydrate antigens are a viable option for parasite vaccine development, given the proven success of carbohydrate vaccines to combat bacterial infections. We will review the key components of carbohydrate vaccines that have remained largely consistent since their inception, and the success of bacterial carbohydrate vaccines. We will then explore the latest developments for both traditional and non-traditional carbohydrate vaccine approaches for three of the world's major protozoan parasitic diseases-malaria, toxoplasmosis, and leishmaniasis. The traditional prophylactic carbohydrate vaccine strategy is being explored for malaria. However, given that parasite disease biology is complex and often arises from host immune responses to parasite antigens, carbohydrate vaccines against deleterious immune responses in host-parasite interactions are also being explored. In particular, the highly abundant glycosylphosphatidylinositol molecules specific for , and spp. are considered exploitable antigens for this non-traditional vaccine approach. Discussion will revolve around the application of these protozoan carbohydrate antigens for vaccines currently in preclinical development.
Topics: Adjuvants, Immunologic; Animals; Antigens, Protozoan; Bacterial Vaccines; Carbohydrates; Glycosylphosphatidylinositols; Host-Parasite Interactions; Humans; Leishmania; Leishmaniasis; Malaria; Malaria Vaccines; Parasites; Parasitic Diseases; Plasmodium; Protozoan Vaccines; Toxoplasma; Toxoplasmosis; Vaccination
PubMed: 28660174
DOI: 10.3389/fcimb.2017.00248 -
Parasitology Sep 2014Toxoplasma gondii is a cosmopolitan protozoan parasite that infects a wide range of mammal and bird species. Common infection leads to high economic (e.g., abortions in... (Review)
Review
Toxoplasma gondii is a cosmopolitan protozoan parasite that infects a wide range of mammal and bird species. Common infection leads to high economic (e.g., abortions in sheep) and human (e.g., congenital toxoplasmosis or neurotoxoplasmosis in humans) losses. With one exception (Toxovax for sheep), there are no vaccines to prevent human or animal toxoplasmosis. The paper presents the current state and challenges in the development of a vaccine against toxoplasmosis, designed for farm animals either bred for consumption or commonly kept on farms and involved in parasite transmission. So far, the trials have mostly revolved around conventional vaccines and, compared with the research using laboratory animals (mainly mice), they have not been very numerous. However, the results obtained are promising and could be a good starting point for developing an effective vaccine to prevent toxoplasmosis.
Topics: Animals; Animals, Domestic; Antibodies, Protozoan; Antigens, Protozoan; Humans; Protozoan Proteins; Protozoan Vaccines; Toxoplasma; Toxoplasmosis, Animal
PubMed: 24805159
DOI: 10.1017/S0031182014000481 -
Microbial Pathogenesis Jun 2021Toxoplasma gondii is a protozoan coccidian parasite belonging to Phylum Apicomplexa and is the causative agent of toxoplasmosis as a zoonotic disease around the world.... (Review)
Review
Toxoplasma gondii is a protozoan coccidian parasite belonging to Phylum Apicomplexa and is the causative agent of toxoplasmosis as a zoonotic disease around the world. It is one of the most important protozoa which is transmitted via various routes and infects several warm-blooded animals. The seroprevalence of T. gondii infection is high worldwide and leads to clinical, psychological, and economic problems. At present, available drug therapy for toxoplasmosis has severe side effects, so the development of new anti-toxoplasma drugs or effective vaccines is mandatory. Therefore, different measures have been taken for the development of anti-toxoplasmosis vaccines, and various studies have shown that DNA vaccines could be one of the most successful approaches against the intracellular parasite, T. gondii. Many of these studies have evaluated the efficacy of immunogenicity and different aspects of the DNA vaccines for toxoplasmosis including single genes or multi-gene plasmids with or without adjuvants. Most of the literature confirms that DNA vaccines containing different antigens of the toxoplasma parasite can induce suitable immune response and protection in acute or chronic toxoplasmosis. Therefore, in this review article, we aimed to discuss the current status of DNA vaccines as a new immunization method against toxoplasmosis.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Immunization; Protozoan Proteins; Protozoan Vaccines; Seroepidemiologic Studies; Toxoplasma; Toxoplasmosis; Toxoplasmosis, Animal; Vaccines, DNA
PubMed: 33930415
DOI: 10.1016/j.micpath.2021.104888 -
Frontiers in Immunology 2021
Topics: Animals; Female; Host-Parasite Interactions; Humans; Parasites; Pregnancy; Pregnancy Complications, Parasitic; Protozoan Vaccines
PubMed: 34975925
DOI: 10.3389/fimmu.2021.813446 -
Frontiers in Immunology 2018Extracellular vesicles (EVs) are small membrane-surrounded structures released by different kinds of cells (normal, diseased, and transformed cells) and that contain... (Review)
Review
Extracellular vesicles (EVs) are small membrane-surrounded structures released by different kinds of cells (normal, diseased, and transformed cells) and that contain large amounts of important substances (such as lipids, proteins, metabolites, DNA, RNA, and non-coding RNA (ncRNA), including miRNA, lncRNA, tRNA, rRNA, snoRNA, and scaRNA) in an evolutionarily conserved manner. EVs, including exosomes, play a role in the transmission of information, and substances between cells that is increasingly being recognized as important. In some infectious diseases such as parasitic diseases, EVs have emerged as a ubiquitous mechanism for mediating communication during host-parasite interactions. EVs can enable multiple modes to transfer virulence factors and effector molecules from parasites to hosts, thereby regulating host gene expression, and immune responses and, consequently, mediating the pathogenic process, which has made us rethink our understanding of the host-parasite interface. Thus, here, we review the present findings regarding EVs (especially exosomes) and recognize the role of EVs in host-parasite interactions. We hope that a better understanding of the mechanisms of parasite-derived EVs may provide new insights for further diagnostic biomarker, vaccine, and therapeutic development.
Topics: Animals; Antiprotozoal Agents; Biomarkers; Exosomes; Host-Parasite Interactions; Humans; Parasites; Parasitic Diseases; Protozoan Vaccines; Virulence Factors
PubMed: 30697211
DOI: 10.3389/fimmu.2018.03066